Entrectinib serves as an oral inhibitor targeting the tyrosine kinases TRKA/B/C, ROS1, and ALK, and is utilized in the treatment of solid tumors that harbor NTRK gene fusions as well as non-small cell lung cancer featuring ROS1 mutations (111). The gene discussed is ROS1; the disease is non-small cell lung carcinoma.